DRMA
DRMA
NASDAQ · Biotechnology

Dermata Therapeutics Inc

$1.32
+0.02 (+1.54%)
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +2,837.9% upside
Low Target $26.82
Average Target $38.78
High Target $44.92
Current Price $1.32
Current
$1.32
Target
$38.78
$26.82 $38.78 avg $44.92
Scenario Analysis
Bear Case
$26.82
1,931.8%
Low target
Base Case
$38.78
+2,837.9%
Avg target
Bull Case
$44.92
+3,303.0%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$8.00
-83.5% from high
52-Week Low
$1.10
+20.0% from low
Target vs 52W High
$38.78
+384.8% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 78% $257.58 +2.4%
AMGN
Amgen Inc
Hold 44 50% $190.87 -47.2%
GILD
Gilead Sciences Inc
Strong Buy 39 82% $362.68 +187.5%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 40 83% $438.34 -11.4%
REGN
Regeneron Pharmaceuticals
Buy 38 71% $76.80 -87.8%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 37 76% $102.31 -65.6%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -38.5%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -48.0%